The collaboration combines Salipro Biotech’s unique expertise and its Salipro® platform technology to stabilise challenging drug targets from Boehringer Ingelheim’s drug discovery programs to enable ...
On Tuesday, Boehringer Ingelheim’s Empagliflozin became off-patent in India. Major domestic drugmakers are expected to launch their generic versions soon. According to the company’s statement ...
(Image Credits: Pixabay) Boehringer Ingelheim’s blockbuster diabetes drug, Empagliflozin, is now off-patent in India, paving the way for domestic drugmakers to launch generic versions.
Top 20 biopharma goes live with Veeva Development Cloud to speed the delivery of treatments for currently incurable diseases "Together with Veeva, Boehringer has advanced its approach to clinical ...
Some media reports have been oversimplistically juxtaposing the two decisions, either lamenting or celebrating the Christian character as a repudiation of the trans one, when of course ...
Boehringer Ingelheim GmbH terminated its second metabolic dysfunction-associated steatohepatitis (MASH) alliance on March 6, ending an $870 million license agreement inked with Yuhan Corp. for dual ...
Late last week, Christian geneticist Francis Collins resigned abruptly as a researcher at the National Institutes of Health (NIH). On Wednesday this week, the U.S. Senate held a confirmation hearing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback